Quality Control in Compounded Peptides: USP Standards Explained

The phrase "compounded peptide" gets used so loosely in marketing that it can blur the meaningful differences between products that are prepared under a serious quality system and products that are not. The distinction matters because peptides are typically injected, and injectable medications carry an inherent risk if they are contaminated, mislabeled, or incorrectly dosed. The framework that separates a licensed compounded peptide from anything else is the United States Pharmacopeia, commonly abbreviated as USP.

This article explains the USP standards that govern peptide compounding, what sterility testing actually involves, how environmental monitoring works in a cleanroom, and the practical questions a patient can ask to confirm that their medication is being prepared under a real quality program.

The role of USP

The United States Pharmacopeia is a nonprofit, scientific organization that publishes official quality standards for medicines, food ingredients, and dietary supplements. The federal Food, Drug, and Cosmetic Act gives USP standards legal force. When state boards of pharmacy inspect compounding pharmacies, USP chapters are the technical reference points.

For peptide compounding, three USP chapters are most relevant.

USP 795 covers non-sterile compounding. This includes oral capsules, topical creams, and similar preparations that do not require sterile conditions.

USP 797 covers sterile compounding. This is the chapter that matters most for injectable peptides because contamination of an injectable medication can cause serious infection.

USP 800 covers the handling of hazardous drugs and is more about protecting personnel than about patient-specific quality.

A peptide compounding pharmacy that prepares injectable medications operates primarily under USP 797, with USP 795 applying to any oral or topical preparations and USP 800 applying when relevant.

Inside USP 797

USP 797 is detailed and technical. The chapter has been revised several times, with the most recent significant revision becoming officially compendial in 2023. The core elements of the chapter are:

Categorization of compounded sterile preparations. The chapter classifies preparations into categories based on the storage conditions, the testing performed, and the resulting beyond-use date. Categories range from preparations that must be used within hours to preparations that, after appropriate testing, can be assigned longer beyond-use dates.

Facility design requirements. The chapter specifies what kind of physical environment is required for sterile compounding. The work must occur in an ISO Class 5 primary engineering control, which is typically a laminar airflow workbench or a biological safety cabinet. The primary engineering control must be located within an ISO Class 7 buffer area, which in turn is accessed through an ISO Class 8 ante room. ISO classifications refer to the maximum number of airborne particles allowed per cubic meter at specific particle sizes.

Personnel training and competency. Pharmacists and technicians must complete documented training, demonstrate competency through gowning evaluations, and pass media-fill tests that simulate the compounding process to confirm aseptic technique.

Environmental monitoring. The chapter requires routine sampling of air, surfaces, and personnel to detect microbial contamination. Results must be trended and acted upon when they exceed action levels.

Cleaning and disinfection. The chapter specifies what agents must be used, how often surfaces must be cleaned, and how cleaning effectiveness is verified.

Sterility testing. For preparations assigned longer beyond-use dates, sterility testing is required.

Documentation. Every step is documented, from the receipt of the active pharmaceutical ingredient to the labeling of the final preparation.

This is the framework that separates licensed compounded peptides from anything prepared outside this system.

Cleanroom classification in practice

The ISO classifications described in USP 797 translate into a physical environment that looks quite different from a typical pharmacy back room.

An ISO Class 5 environment, where the actual compounding occurs, allows no more than 3,520 particles of 0.5 micrometers or larger per cubic meter of air. This is achieved through HEPA filtration and laminar airflow that pushes filtered air across the work surface in a unidirectional pattern. The pharmacist works inside this airflow with sterile gloves, sleeves, and tools.

The ISO Class 7 buffer area surrounding the primary engineering control allows up to 352,000 particles of 0.5 micrometers or larger per cubic meter, again maintained through HEPA filtration and air exchange rates of at least 30 air changes per hour.

The ISO Class 8 ante room is the gowning and entry zone. Personnel enter here, perform hand hygiene, gown into sterile attire, and then move into the buffer area.

This is a controlled environment in the technical sense. Air pressure is maintained so that air flows from cleaner zones to less clean zones, never the reverse. Surfaces are designed to be cleaned and disinfected. Pass-through chambers handle material movement to minimize traffic.

A pharmacy that says it follows USP 797 is committing to maintaining this environment continuously, not just during inspections.

Environmental monitoring and what it detects

Environmental monitoring is one of the most important elements of a sterile compounding quality system. The goal is to detect microbial contamination before it reaches a patient.

A typical environmental monitoring program includes:

Viable air sampling, where a calibrated air sampler draws a measured volume of air through a microbiological growth medium. The plates are then incubated, and any colony-forming units are counted. Results are trended over time, and action levels trigger investigation when exceeded.

Surface sampling, where contact plates or swabs are pressed against work surfaces, hood walls, and frequently touched objects. The plates are incubated and the colony-forming units counted.

Personnel sampling, where compounding staff are sampled by pressing contact plates against their gloved fingertips after compounding activity. This is a direct test of aseptic technique.

Total particle counting, where airborne particle counters are used to verify that the ISO classifications are being maintained.

When an action level is exceeded, the pharmacy is expected to investigate, identify the source, take corrective action, and document the response. This is why environmental monitoring is more than a checkbox. It is an ongoing feedback loop that informs the operation.

Sterility testing of compounded preparations

For compounded preparations that will be stored for more than a short period, USP 797 requires sterility testing. The testing process is governed by USP 71, which is the chapter on sterility tests.

The basic approach involves transferring a sample of the final preparation into nutrient media, incubating for a defined period (typically 14 days), and observing for microbial growth. Two media are typically used to capture a wide range of potential contaminants. If growth is detected, the lot is investigated and may be discarded.

A licensed compounding pharmacy maintains documentation of every sterility test performed, including the lot tested, the media used, the incubation period, the result, and the disposition of the lot. Patients can ask whether sterility testing is performed on their medication and what the typical turnaround time is.

It is worth noting that sterility testing is not the only quality measure. The combination of trained personnel, ISO-classified environment, environmental monitoring, validated cleaning procedures, and documented compounding records provides assurance. Sterility testing is the final confirmation, not the only safeguard.

Stability and beyond-use dating

Once a peptide is compounded, the next quality question is how long it remains chemically stable and microbiologically safe. The beyond-use date (BUD) is the answer.

USP 797 sets default beyond-use dates based on the category of preparation and the storage conditions. A pharmacy can assign longer beyond-use dates only when supporting stability data are available. Stability data come from chemical assays that measure how much of the active peptide remains intact at various time points under defined storage conditions.

For peptides in particular, stability matters because peptide molecules can degrade through hydrolysis, oxidation, or aggregation. A poorly formulated or improperly stored peptide can lose potency or form impurities. A reputable pharmacy bases its beyond-use dates on documented stability data, not guesses.

When a patient receives a compounded peptide, the label should display the beyond-use date clearly. Storage instructions should also be provided. Following those instructions matters.

Active pharmaceutical ingredients matter

Quality of the final compounded preparation cannot exceed the quality of the starting materials. The active pharmaceutical ingredient (API) used must come from an FDA-registered facility and arrive with a certificate of analysis that documents identity, purity, and potency.

A reputable compounding pharmacy:

Sources APIs only from registered, audited suppliers.

Reviews each certificate of analysis and retains documentation.

May perform additional identity testing in-house before using the API in compounding.

Maintains chain-of-custody records linking each finished preparation back to the specific API lot used.

This traceability is part of what separates a licensed pharmacy from any unregulated source.

What patients can ask

A patient receiving a compounded peptide is entitled to ask questions about how the medication was prepared. Useful questions include:

Is the pharmacy compliant with USP 797? When was the most recent third-party audit?

Is the pharmacy PCAB accredited?

What sterility testing is performed on my medication, and is the documentation available on request?

What is the beyond-use date, and how was it determined?

Where does the active pharmaceutical ingredient come from, and is a certificate of analysis available?

A pharmacy operating a serious quality program will answer these questions directly. A source that cannot answer them, or that becomes evasive when asked, is signaling something important.

How TelePeptide Health approaches quality

Within the TelePeptide Health model, prescriptions are routed to 503A compounding pharmacies that document their USP 797 compliance, hold relevant accreditations, and operate documented sterility testing and environmental monitoring programs. The clinical team and the pharmacy collaborate so that each medication arriving at a patient's door is supported by a documented quality program.

Patients can ask their clinician about the specific pharmacy filling their prescription and the quality documentation available. Transparency at this layer is part of what makes a telehealth peptide therapy model legitimate.

The takeaway

Quality control in compounded peptides is not abstract. It is a series of concrete practices: a cleanroom that meets ISO classifications, a personnel program that documents competency, an environmental monitoring system that detects contamination, a sterility testing protocol that confirms what the rest of the system already controlled for, and a documentation trail that links each finished preparation back to the materials and processes that produced it.

USP 797 is the framework that ties these elements together. A pharmacy that follows USP 797 is signaling that it has invested in the facility, the staff training, the testing equipment, and the documentation systems required to compound sterile medications safely. A source that operates outside this framework, regardless of how the products are marketed, is not in the same category.

For patients receiving prescribed peptide therapy, the quality program behind the medication is as important as the prescription itself. Asking about it is reasonable, expected, and welcomed by any pharmacy that is doing the work properly.